Immunoassay Neurological Biomarkers Market Size, Share Outlook, Growth Analysis Report and Forecast Trends 2026-2030

The immunoassay neurological biomarkers market covers diagnostic platforms including ELISA, chemiluminescent immunoassay, and multiplex systems that detect biomarkers associated with neurological diseases in blood, cerebrospinal fluid, and other biological samples. These assays serve critical roles in early disease diagnosis, patient stratification, and treatment monitoring. Market estimates for 2025 place the global value between approximately $713 million and $989 million across major industry analyses, with projections suggesting the market will reach $2.1 to $2.2 billion by 2032 or 2033.

• •Market valued at roughly $900 million in 2025, with estimates ranging from $713 million to $989 million across sources
• •Projected to reach $2.1-2.2 billion by 2032-2033, representing substantial growth over the forecast period
• •Growth rates cited across sources range from approximately 8.6% to 17.9% CAGR, with multiple estimates clustering around 17%

The escalating global burden of neurodegenerative diseases is the primary catalyst, as aging demographics and lifestyle risk factors continue to expand the patient population requiring biomarker testing. Recent regulatory approvals of disease-modifying Alzheimer's therapies have created demand for companion diagnostic biomarkers capable of identifying eligible patients and tracking therapeutic response. Additionally, technological advances in assay sensitivity are enabling practical blood-based testing, reducing dependence on invasive cerebrospinal fluid sampling and expanding clinical utility.

• •Rising prevalence of Alzheimer's, Parkinson's, and other neurodegenerative disorders is expanding the addressable patient population
• •Breakthrough FDA approvals for Alzheimer's therapies are driving demand for companion diagnostics and patient stratification biomarkers
• •Advances in ultrasensitive immunoassay technology are enabling practical blood-based tests that replace more invasive sampling methods

The market is segmented by product into consumables, primarily reagents and assay kits, and diagnostic instruments, with reagents commanding the largest share due to their recurring use in clinical laboratory workflows. Assay platforms include ELISA, chemiluminescent immunoassay, and multiplex systems, each serving distinct clinical and research applications. Geographically, North America leads the market, supported by advanced healthcare infrastructure, high disease prevalence, substantial R&D investment, and favorable regulatory pathways for novel diagnostic technologies.

• •Reagents and consumables hold the largest market share, driven by repeat purchasing in clinical and research laboratories
• •North America is the leading regional market, followed by Europe and the Asia-Pacific region
• •Key assay platforms include ELISA, chemiluminescent immunoassay, and multiplex systems optimized for high-throughput clinical applications

What are the recent trends and outlook?

The market is trending toward more sensitive, automated, and multiplexed immunoassay platforms capable of simultaneously measuring multiple biomarkers from small sample volumes. Blood-based testing is gaining significant momentum as a less invasive and more practical alternative to cerebrospinal fluid analysis, with several high-sensitivity plasma assays now reaching clinical validation and adoption. Continued investment in neurological R&D, expanding immunoassay applications to additional neurological indications, and integration of biomarker testing into routine clinical practice are expected to sustain strong market momentum through the coming decade.

• •Multiplex immunoassay platforms enabling simultaneous measurement of multiple biomarkers are gaining both clinical and research traction
• •Blood-based ultrasensitive assays are emerging as practical clinical alternatives to cerebrospinal fluid testing for key neurological applications
• •The broader neurological biomarkers market, encompassing imaging, proteomic, and genomic markers, is forecast to reach $9-19 billion by the early 2030s